[gurchik]

The patent for semaglutide doesn't expire until 2030 (in the US), so a generic is not currently available. I say this as someone who is looking into purchasing the drug: I don't think many people buying the compounded formula know it is not a "generic" and is not FDA approved. The companies selling it often do not even say where it comes from.

It shouldn't be surprising that Novo Nordisk is fighting these compounding pharmacies that are purely interested in undercutting them. Not to say they need our sympathy, since I'm sure a significant cost of Ozempic is due to the injection pen with a million patents.

[toomuchtodo]

The pill version is showing similar safety and efficacy profiles as the injectable (leveraging higher dosage to get through the gut to the bloodstream), so runs to Canada and Mexico are probably in consumer futures to evade patent regulatory capture until 2030 (or getting it mailed from India, I have had personal success with this for other non controlled pharma products).

[Someone1234]

> The pill version is showing similar safety and efficacy profiles as the injectable

The pill, Rybelsus, barely works. They've having to put 700%+ more than the injections to still get a lower overall effectiveness. They're actively working on alternative delivery methods to resolve this.

A daily pill GLP-1 will be a massive commercial success. Rybelsus isn't very good for either the manufacturer or the consumer. You're burning a lot of expensive peptide to get a worse outcome at every dose level.

[kurthr]

Yeah, but the Mounjaro/Zepbound cost with injector in the UK is £139 for 4 weekly 5mg injections/month. They're still making over 90% margins. The margins in the US are completely insane >99%.

https://www.simpleonlinepharmacy.co.uk/online-doctor/weight-...

[Suppafly]

>The patent for semaglutide doesn't expire until 2030 (in the US), so a generic is not currently available.

Aren't there a handful of similar drugs in that class though? I wonder if some of them come off patent sooner.

[sithadmin]

Victoza (liraglutide)'s patent expired, but its effect on weight loss is pitiful relative to later-generation GLP-1 agonists. Same story for Trulicity (dulaglutide), for which patent protections end in 2027.

[cthalupa]

Most are newer, so the patents will expire later.

Liraglutide is an older version that is now available as a generic, but it's results, particularly for weight loss, are far behind semaglutide, tirzepatide, etc.